{
    "eid": "2-s2.0-85119829406",
    "title": "Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis",
    "cover-date": "2021-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Genetics",
            "@code": "1311",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "cancer immunotherapy",
        "Immune-checkpoint inhibitors",
        "Immune-related adverse events",
        "Overall survival",
        "Thailand"
    ],
    "authors": [
        "Nuttapong Ngamphaiboon",
        "Suthinee Ithimakin",
        "Teerada Siripoon",
        "Nattaya Sintawichai",
        "Virote Sriuranpong"
    ],
    "citedby-count": 7,
    "ref-count": 27,
    "ref-list": [
        "An update on immunotherapy for solid tumors: a review",
        "Immune-related adverse events associated with immune checkpoint blockade",
        "Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions",
        "Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis",
        "Fine-tuning Cancer immunotherapy: optimizing the gut microbiome",
        "Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials",
        "Phase III KEYNOTE-048 study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma: Asia vs non-Asia subgroup analysis",
        "Atezolizumab in Japanese patients with previously treated advanced non-small-cell lung Cancer: a subgroup analysis of the phase 3 OAK study",
        "Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the phase III CheckMate 025 study",
        "Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China study",
        "Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial",
        "Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline",
        "Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up",
        "Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group",
        "Nivolumab plus Ipilimumab in advanced non-small-cell lung Cancer",
        "Safety profile of Nivolumab Monotherapy: a pooled analysis of patients with advanced melanoma",
        "Immune-related thyroiditis with immune checkpoint inhibitors",
        "Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade",
        "Combined Nivolumab and Ipilimumab or Monotherapy in untreated melanoma",
        "Management of immune-related adverse events and kinetics of response with ipilimumab",
        "Association of pre-existing thyroid autoimmunity with the development of thyroid dysfunction induced by nivolumab",
        "Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?",
        "Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients",
        "Association of Immune-Related Adverse Events with clinical benefit in patients with advanced non-small-cell lung Cancer treated with Nivolumab",
        "Association between immune-related adverse events and clinical efficacy in patients with melanoma treated with Nivolumab: a multicenter retrospective study"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60199578",
            "affilname": "Ramathibodi Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199578",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60199575",
            "affilname": "Siriraj Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Ramathibodi Hospital",
        "Thailand Research Fund"
    ]
}